000303114 001__ 303114
000303114 005__ 20250727021739.0
000303114 0247_ $$2doi$$a10.1182/bloodadvances.2025016276
000303114 0247_ $$2pmid$$apmid:40706037
000303114 0247_ $$2ISSN$$a2473-9529
000303114 0247_ $$2ISSN$$a2473-9537
000303114 0247_ $$2altmetric$$aaltmetric:179651867
000303114 037__ $$aDKFZ-2025-01533
000303114 041__ $$aEnglish
000303114 082__ $$a610
000303114 1001_ $$aAbu Ahmad, Muhammad$$b0
000303114 245__ $$aHLA-E[pHLA-G] Complex Specific Monoclonal Antibody Enhancing NK Activity in Multiple Myeloma.
000303114 260__ $$aWashington, DC$$bAmerican Society of Hematology$$c2025
000303114 3367_ $$2DRIVER$$aarticle
000303114 3367_ $$2DataCite$$aOutput Types/Journal article
000303114 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1753449955_24371
000303114 3367_ $$2BibTeX$$aARTICLE
000303114 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000303114 3367_ $$00$$2EndNote$$aJournal Article
000303114 500__ $$aepub
000303114 520__ $$aHLA-E presenting the HLA-G leader peptide VMAPRTLFL (HLA-E[pHLA-G]) on tumor cells plays a crucial role in suppressing natural killer(NK) and cytotoxic CD8+ T cells through NKG2A interaction. While blocking HLA-E:NKG2A is a promising immune checkpoint(IC) approach in cancer therapy, toxicity remains a major clinical concern. We developed a novel immune checkpoint inhibitor(ICI) that selectively prevents HLA-E:NKG2A interaction, a monoclonal antibody(mAb) that selectively targets the HLA-E[pHLA-G] complex, distinguishing cancerous from non-cancerous cells. In clinical bone marrow samples from multiple myeloma(MM) patients, 4D7 specifically recognized tumor-associated HLA-E-peptide complexes. Using NK cells from healthy donors, 4D7 effectively blocked the HLA-E:NKG2A interaction and enhanced NKG2A-positive NK cell activity in autologous MM cell co-cultures. Importantly, 4D7 did not inhibit NKG2C-positive NK cells, preserving their activity. Even though NKG2C also interacts with HLA-E. In MM-bearing mice treated with human NK cells, 4D7 significantly reduced tumor growth. This targeted approach activates NK cells only against tumor cells presenting HLA-E-peptide complexes, potentially minimizing toxicity compared to current NKG2A inhibitors. The development of 4D7 highlights a promising advancement in immunotherapy for hematological malignancies, offering improved outcomes for MM patients and a foundation for broader application across cancer types.
000303114 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000303114 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000303114 7001_ $$aRadinsky, Olga$$b1
000303114 7001_ $$00000-0001-7740-0473$$aKaufman, Bar$$b2
000303114 7001_ $$00000-0002-0665-9370$$aWaidha, Kamran$$b3
000303114 7001_ $$aGharra, Eman$$b4
000303114 7001_ $$aDim, Sharon$$b5
000303114 7001_ $$aManikandan, Dinesh Babu$$b6
000303114 7001_ $$aOfir, Noa$$b7
000303114 7001_ $$0P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1$$aJäger, Dirk$$b8$$udkfz
000303114 7001_ $$0P:(DE-He78)27b8b96bde8e36bbbc5e91485b08411a$$aMeyer, Marten$$b9$$udkfz
000303114 7001_ $$00000-0003-3634-9098$$aElkabets, Moshe$$b10
000303114 7001_ $$00000-0003-4665-7326$$aCampbell, Kerry S$$b11
000303114 7001_ $$00000-0001-6228-9135$$aZektser, Miri$$b12
000303114 7001_ $$00000-0002-0548-2147$$aGazit, Roi$$b13
000303114 7001_ $$aRouvio, Ory$$b14
000303114 7001_ $$0P:(DE-He78)b2290261145f21c46f2d42783c69d104$$aMomburg, Frank$$b15$$udkfz
000303114 7001_ $$aPorgador, Angel$$b16
000303114 773__ $$0PERI:(DE-600)2876449-3$$a10.1182/bloodadvances.2025016276$$gp. bloodadvances.2025016276$$pnn$$tBlood advances$$vnn$$x2473-9529$$y2025
000303114 909CO $$ooai:inrepo02.dkfz.de:303114$$pVDB
000303114 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000303114 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)27b8b96bde8e36bbbc5e91485b08411a$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000303114 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b2290261145f21c46f2d42783c69d104$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000303114 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000303114 9141_ $$y2025
000303114 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBLOOD ADV : 2022$$d2024-12-16
000303114 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-16
000303114 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-16
000303114 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-07-05T12:07:28Z
000303114 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-07-05T12:07:28Z
000303114 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-07-05T12:07:28Z
000303114 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-16
000303114 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-16
000303114 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-16
000303114 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-16
000303114 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-16
000303114 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-16
000303114 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-16
000303114 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-16
000303114 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBLOOD ADV : 2022$$d2024-12-16
000303114 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-16
000303114 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-16
000303114 9201_ $$0I:(DE-He78)D120-20160331$$kD120$$lAngewandte Tumor-Immunität$$x0
000303114 980__ $$ajournal
000303114 980__ $$aVDB
000303114 980__ $$aI:(DE-He78)D120-20160331
000303114 980__ $$aUNRESTRICTED